Investigating T Cell Immunity in Cancer : Achievements and Prospects
T cells play a key role in tumour surveillance, both identifying and eliminating transformed cells. However, as tumours become established they form their own suppressive microenvironments capable of shutting down T cell function, and allowing tumours to persist and grow. To further understand the tumour microenvironment, including the interplay between different immune cells and their role in anti-tumour immune responses, a number of studies from mouse models to clinical trials have been performed. In this review, we examine mechanisms utilized by tumour cells to reduce their visibility to CD8+ Cytotoxic T lymphocytes (CTL), as well as therapeutic strategies trialled to overcome these tumour-evasion mechanisms. Next, we summarize recent advances in approaches to enhance CAR T cell activity and persistence over the past 10 years, including bispecific CAR T cell design and early evidence of efficacy. Lastly, we examine mechanisms of T cell infiltration and tumour regression, and discuss the strengths and weaknesses of different strategies to investigate T cell function in murine tumour models.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 22(2021), 6 vom: 12. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zeng, Zhen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CAR |
|---|
| Anmerkungen: |
Date Completed 20.04.2021 Date Revised 20.04.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms22062907 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323648568 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323648568 | ||
| 003 | DE-627 | ||
| 005 | 20231225184632.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms22062907 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1078.xml |
| 035 | |a (DE-627)NLM323648568 | ||
| 035 | |a (NLM)33809369 | ||
| 035 | |a (PII)2907 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zeng, Zhen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Investigating T Cell Immunity in Cancer |b Achievements and Prospects |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.04.2021 | ||
| 500 | |a Date Revised 20.04.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a T cells play a key role in tumour surveillance, both identifying and eliminating transformed cells. However, as tumours become established they form their own suppressive microenvironments capable of shutting down T cell function, and allowing tumours to persist and grow. To further understand the tumour microenvironment, including the interplay between different immune cells and their role in anti-tumour immune responses, a number of studies from mouse models to clinical trials have been performed. In this review, we examine mechanisms utilized by tumour cells to reduce their visibility to CD8+ Cytotoxic T lymphocytes (CTL), as well as therapeutic strategies trialled to overcome these tumour-evasion mechanisms. Next, we summarize recent advances in approaches to enhance CAR T cell activity and persistence over the past 10 years, including bispecific CAR T cell design and early evidence of efficacy. Lastly, we examine mechanisms of T cell infiltration and tumour regression, and discuss the strengths and weaknesses of different strategies to investigate T cell function in murine tumour models | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CAR | |
| 650 | 4 | |a CD8 T cells | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a checkpoint inhibitor | |
| 650 | 4 | |a cytotoxic T lymphocytes | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a tumour antigen | |
| 700 | 1 | |a Chew, Hui Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Cruz, Jazmina G |e verfasserin |4 aut | |
| 700 | 1 | |a Leggatt, Graham R |e verfasserin |4 aut | |
| 700 | 1 | |a Wells, James W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 22(2021), 6 vom: 12. März |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:6 |g day:12 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms22062907 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 6 |b 12 |c 03 | ||